1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Remibrutinib REMIXes The Itch Record

 
• By Elizabeth Cairns

Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.  

Itching

Novartis AG and Roche Holding AG’s Xolair (omalizumab) has held a monopoly in chronic spontaneous urticaria for some years. Now, though, another agent might end Xolair’s solo reign: Novartis’s own remibrutinib.

Key Takeaways
  • Novartis’s remibrutinib looks set to join Xolair as an approved therapy for chronic spontaneous urticaria
  • But Celldex’s barzolvolimab, at an earlier stage of development, looks as good...

New data from the twin pivotal trials of remibrutinib, REMIX-1 and -2, suggest that the BTK inhibitor works well whether or not patients have previously taken Xolair. This could, theoretically,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

More from R&D

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.